Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,780.40
(
-0.07%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
104.36
(
-2.08%
)
Bitcoin
70,451.20
(
-1.11%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: xrymd post# 154714

Monday, 12/31/2012 12:09:40 PM

Monday, December 31, 2012 12:09:40 PM

Post# of 257262
XOMA—Uveitis is a larger market than many investors realize.

Now they seem to be taking a shot at CV. Seems like a stretch for them.

The Gevokizumab program in CV disease is funded and owned by Servier. I ascribe no value to the CV program, so if anything does become of it, it’s all upside as far as I’m concerned.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now